Sensasure Technologies Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sensasure Technologies Inc (SSTC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sensasure Technologies Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 156,186M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+109.4% annualized vs trailing 12 months), vs accelerating (+32.0%) for its tracked peer group.
- Growth: Sensasure Technologies Inc generated -14.2% revenue growth year over year in 2025 2024, vs 3.6% for its tracked competitors combined.
- Profitability: Its -1,483.3% net margin compares with 21.8% for the peer group.
- Peer revenue share: Sensasure Technologies Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SSTC Sales vs. its Competitors, 2025 2024
Sensasure Technologies Inc reported revenue contraction of 14.22 % year on year in 2025 2024, below its competitors' combined revenue growth of 3.61 %.
With a net margin of -1,483.26 %, Sensasure Technologies Inc reported lower profitability than its competitors (21.81 %).
Sensasure Technologies Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Sensasure Technologies Inc vs. its Competitors, 2025 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sensasure Technologies Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sensasure Technologies Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sensasure Technologies Inc's competitor groups requires a Commercial License.
For context: the Oil And Gas Production industry grew revenue 3.4% year over year, combined, vs -14.2% for Sensasure Technologies Inc. Sensasure Technologies Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Sensasure Technologies Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sensasure Technologies Inc | No | - | - | Yes |
| Competitors combined (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SSTC Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Edwards Lifesciences Corporation | 282.9% | Outperformed |
| 2 | Medtronic Plc | 282.9% | Outperformed |
| 3 | Koninklijke Philips Nv | 282.9% | Outperformed |
| 4 | Abbott Laboratories | 282.9% | Outperformed |
| 5 | Stryker Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sensasure Technologies Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sensasure Technologies Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Sensasure Technologies Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Sensasure Technologies Inc | - | 0.12 |
| Abbott Laboratories | 172,663.22 | 45,134.00 |
| Medtronic Plc | 110,891.28 | 37,542.00 |
| Stryker Corp | 106,300.54 | 25,837.00 |
| Boston Scientific Corporation | 64,375.02 | 20,997.00 |
| Edwards Lifesciences Corporation | 49,858.43 | 6,512.50 |
| SUBTOTAL | 527,602.45 | 156,186.13 |
Sign in to see all competitors of Sensasure Technologies Inc.
Sources: Sensasure Technologies Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sensasure Technologies Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sensasure Technologies Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 17.78 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Edwards Lifesciences Corporation | United States 57.64 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sensasure Technologies Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sensasure Technologies Inc | - | - | - |
| Abbott Laboratories | 172,663 | 392,470 | 54,574 |
| Medtronic Plc | 110,891 | 395,179 | 55,463 |
| Stryker Corp | 106,301 | 461,375 | 66,589 |
| Boston Scientific Corporation | 64,375 | 355,881 | 62,186 |
| Edwards Lifesciences Corporation | 49,858 | 407,031 | 62,725 |
| PEERS TOTAL | 527,602 | 381,482 | 51,196 |
Sign in to see all peers for Sensasure Technologies Inc.
Sensasure Technologies Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 61.62 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sensasure Technologies Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 113 companies in Sensasure Technologies Inc's industry classification, broader than the peer set above. Market cap in millions of $.Sensasure Technologies Inc ranks #0 of 113 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 780, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Shell Plc | 285,734 | 19.05 % |
| 2 | Totalenergies Se | 206,896 | 13.79 % |
| 3 | Canadian Natural Resources Limited | 105,045 | 7.00 % |
| 4 | Eni Spa | 94,456 | 6.30 % |
| 5 | Slb Limited | 1,234 | 5.2% |
| 6 | Eog Resources Inc | 1,234 | 5.2% |
| 7 | Cenovus Energy Inc | 1,234 | 5.2% |
| 8 | Occidental Petroleum Corporation | 1,234 | 5.2% |
| 9 | Diamondback Energy Inc | 1,234 | 5.2% |
| 10 | Devon Energy Corp | 1,234 | 5.2% |
| 0 | Sensasure Technologies Inc | 75 | 0.00 % |
Market cap and industry share for the rest of Sensasure Technologies Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2023-04-05.
Sensasure Technologies Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Oil And Gas Production industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (166 companies). See the full Oil And Gas Production industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 56.93 % (avg) | +43.1 pp |
| Operating Margin | -1,601.30 % | industry median | -1,613.2 pp |
| EBITDA Margin | -775.89 % | 11.77 % (avg) | -787.7 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 24.84 % (avg) | -24.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sensasure Technologies Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | -1,185.96 % | -1,601.30 % |
| Return on Invested Capital | - | 87.43 % | 45.25 % | 89.25 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sensasure Technologies Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 780 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 24.84 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Sensasure Technologies Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Sensasure Technologies Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Sensasure Technologies Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Sensasure Technologies Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sensasure Technologies Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 44.2 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+109.4% annualized vs trailing 12 months).
Weaknesses
- Operating margin 1,613.2 points below the industry median.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Sensasure Technologies Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sensasure Technologies Inc | 0.00 | 0.07 | - |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
Sign in to see all peers for Sensasure Technologies Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sensasure Technologies Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sensasure Technologies Inc | Q4 2024 | +10,662.1 % | - |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| PEERS TOTAL | +7.5 % | +65.2 % |
Sign in to see all peers for Sensasure Technologies Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sensasure Technologies Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sensasure Technologies Inc | Q4 2024 | - | - |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
Sign in to see all peers for Sensasure Technologies Inc.
Sensasure Technologies Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sensasure Technologies Inc | - | - | - |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
Sign in to see all peers for Sensasure Technologies Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sensasure Technologies Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sensasure Technologies Inc | - | - |
| Abbott Laboratories | 27.53 | 3.83 |
| Medtronic Plc | 253.79 | 2.95 |
| Stryker Corp | 28.54 | 4.11 |
| Boston Scientific Corporation | 17.69 | 3.07 |
| Edwards Lifesciences Corporation | 49.69 | 7.66 |
| PEERS AVERAGE | 25.17 | 3.38 |
Sign in to see all peers for Sensasure Technologies Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.